Skin Cancer Screenings: Why Are the Benefits in Question?

Main Article Content

Nicholas Brownstone
National Society for Cutaneous Medicine

Darrell Rigel
Icahn School of Medicine at Mount Sinai Hospital

Keywords

melanoma, screening, skin cancer, overdiagnosis

Abstract

Abstract not available. 

References

1. Matsumoto M, Wack S, Weinstock MA, et al. Five-Year Outcomes of a Melanoma Screening Initiative in a Large Health Care System. JAMA Dermatol. Published online April 06, 2022. doi:10.1001/jamadermatol.2022.0253

2. Swerlick RA. Melanoma Screening—Intuition and Hope Are Not Enough. JAMA Dermatol. Published online April 6, 2022. doi:10.1001/jamadermatol.2022.0082

3. Kulkarni RP, Yu WY, Leachman SA. To Improve Melanoma Outcomes, Focus on Risk Stratification, Not Overdiagnosis. JAMA Dermatol. Published online April 6, 2022. doi:10.1001/jamadermatol.2022.0097

4. Rigel DS, Friedman RJ, Kopf AW, et al. Importance of complete cutaneous examination for the detection of malignant melanoma. J Am Acad Dermatol 1986;14:857-60.

5. Geller AG, Zi Z, Sober A, et al. The first 15 years of the American Academy of Dermatology Skin Cancer Screening Programs: 1985-1999. (J Am Acad Dermatol 2003;48:34-41.

6. Siegel R, Miller K, Fuchs H, et al. Cancer statistics, 2022. CA CANCER J CLIN 2022;72:7–33

7. Waqas R. Shaikh, Stephen W. Dusza, Martin A. Weinstock, Susan A. Oliveria, Alan C. Geller, Allan C. Halpern, Melanoma Thickness and Survival Trends in the United States, 1989–2009, JNCI: Journal of the National Cancer Institute, Volume 108, Issue 1, January 2016, djv294, https://doi.org/10.1093/jnci/djv294

Article Sidebar

PDF
Published
May 6, 2022
DOI https://doi.org/10.25251/skin.6.3.1

Article Details

How to Cite
Brownstone, N., & Rigel, D. (2022). Skin Cancer Screenings: Why Are the Benefits in Question? . SKIN The Journal of Cutaneous Medicine, 6(3), 186–188. https://doi.org/10.25251/skin.6.3.1
Issue
Vol. 6 No. 3 (2022)
Section
Editorials
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 1 2 3 4